Recent Press Releases

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® Data from 25 accepted abstracts include...

Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review

Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review SAN DIEGO, Oct 01, 2014 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. ZGNX, +1.74% a...

Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion

Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion Worldwide Collaboration to Market and Develop Portfolio of Soluble Guanylate Cyclase (sGC) Modulators Commences Wednesday,...

The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia

Legal Settlement, Data Presentation, Welfare Initiatives, Acquisition Talks, and Study Results - Research Reports on Shire, Merck, Medtronic, Salix and Johnson & Johnson

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 1, 2014

Abbott Hosts Conference Call for Third-Quarter Earnings

ABBOTT PARK, Ill., Oct.

Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio

THOUSAND OAKS, Calif.

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special...

Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA

LAVAL, Quebec, Sep. 30, 2014 (Canada NewsWire via COMTEX) -- Valeant Pharmaceuticals International, Inc. today announced that the company's Bridgewater, New Jersey location received a Warning...

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing ALISO VIEJO, Calif., Sep 30, 2014 (BUSINESS WIRE) -- GE Healthcare today announced an agreement between its affiliate,...

Johnson & Johnson Announces Agreement To Acquire Alios BioPharma

Acquisition Strengthens Existing Pipeline in Viral Diseases

NEW BRUNSWICK, N.J., Sept.

Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market

Ventana is committed to accelerating the discovery and development of new cancer diagnostic tests that help determine the best course of therapy for each individual patient.

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

Prospects For Leading Players

NEW YORK, Sept. 30, 2014 /PRNewswire/ -- Report Details

RE: public launch of the Open Payments website

September 29, 2014 Marilyn Tavenner Administrator Centers for Medicare & Medicaid Services (CMS) Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 RE:...

MSF URGES PRIME MINISTER MODI TO RESIST U.S. POLITICAL PRESSURE TO RESTRICT GLOBAL ACCESS TO MEDICINES

NEW DELHI/NEW YORK, SEPTEMBER 26, 2014 – As Indian Prime Minister Narendra Modi makes his first official visit to the United States, Doctors Without Borders/Médecins Sans...

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain Marketing Approval Expands Treatment to Include Nearly 11...

Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries

INDIANAPOLIS, Sept. 29, 2014 /PRNewswire/ -- On Oct.

NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization

The Ohio State University Issues Purchase Order For Lab Supplies To NanoLogix

European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer

European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer PRINCETON, N.J., Sep 29, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company...